Alembic Pharmaceuticals Ltd: Stock Analysis & Fundamentals

Updated this week

Alembic Pharmaceuticals Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 20.0. ROE: 11.4%. This stock is not currently in the Nifty 500 momentum outperformers list.

Key Numbers

Current Price

₹674

Dividend Yield

1.63%

Market Cap

13.2K Cr

Valuation

N/A

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd

Strong • 4w streak

+15.9%

Torrent Pharmaceuticals Ltd

Average • 12w streak

+23.4%

Dr Reddys Laboratories Ltd

Zydus Lifesciences Ltd

Weak

+10.0%

← Back to Pharma - Formulators Dashboard

Frequently Asked Questions: Alembic Pharmaceuticals Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Alembic Pharmaceuticals Ltd's latest quarterly results?

Alembic Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -4.3%
Revenue Growth YoY: +10.8%
Operating Margin: 16.0%

What is Alembic Pharmaceuticals Ltd's current PE ratio?

Alembic Pharmaceuticals Ltd's current PE ratio is 20.0x.

Current PE: 20.0x
Market Cap: 13.2K Cr
Dividend Yield: 1.63%

What is Alembic Pharmaceuticals Ltd's price-to-book ratio?

Alembic Pharmaceuticals Ltd's price-to-book ratio is 2.5x.

Price-to-Book (P/B): 2.5x
Book Value per Share: ₹271
Current Price: ₹674

Is Alembic Pharmaceuticals Ltd a fundamentally strong company?

Alembic Pharmaceuticals Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 13.0%

Is Alembic Pharmaceuticals Ltd debt free?

Alembic Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹1,000 Cr

What is Alembic Pharmaceuticals Ltd's return on equity (ROE) and ROCE?

Alembic Pharmaceuticals Ltd's return ratios over recent years

FY2023: ROCE 7.0%
FY2024: ROCE 13.0%
FY2025: ROCE 13.0%

Is Alembic Pharmaceuticals Ltd's cash flow positive?

Alembic Pharmaceuticals Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹88 Cr
Free Cash Flow (FCF): ₹-480 Cr
CFO/PAT Ratio: 15% (weak cash conversion)

What is Alembic Pharmaceuticals Ltd's dividend yield?

Alembic Pharmaceuticals Ltd's current dividend yield is 1.63%.

Dividend Yield: 1.63%
Current Price: ₹674

Who holds Alembic Pharmaceuticals Ltd shares — promoters, FII, DII?

Alembic Pharmaceuticals Ltd's shareholding pattern (Dec 2025)

Promoters: 69.7%
FII (Foreign): 4.2%
DII (Domestic): 16.2%
Public: 9.8%

Is promoter holding increasing or decreasing in Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 69.7% (Dec 2025)
Previous Quarter: 69.7% (Sep 2025)
Change: 0.00% (stable)

Is Alembic Pharmaceuticals Ltd a new momentum entry or an established outperformer?

Alembic Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Alembic Pharmaceuticals Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Alembic Pharmaceuticals Ltd may be worth studying

Cash flow is positive — CFO ₹88 Cr

What is the investment thesis for Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd investment thesis summary:

What is the future outlook for Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.